The Hematology/Oncology Pharmacy Association (HOPA) has launched a collaborative network designed to help hematology/oncology pharmacists and other clinicians to more efficiently navigate complex practice challenges.
On June 26, 2024, the FDA approved epcoritamab-bysp (Epkinly; Abbvie and Genmab) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after ≥2 lines of prior therapy.
